bridgebio attruby news - Search News

FDA, ttr and Attruby

Bridgebio’s Attruby, to Treat Heart Condition ATTR-CM, Receives FDA Approval

Attruby (acoramidis), a near complete TTR stabilizer, has been approved by FDA to reduce cardiovascular death and hospitalization in ATTR-CM patients.

Investor's Business Daily on MSN · 14h

BridgeBio Catapults After Snagging Approval For Its Rival To Pfizer's Heart Drug

BridgeBio Pharma snagged FDA approval for its rival to Pfizer's heart disease treatment, Vyndaqel. BridgeBio stock catapulted.

GlobalData on MSN · 1d

FDA approves BridgeBio’s Attruby for ATTR-CM treatment

The US Food and Drug Administration (FDA) has approved BridgeBio Pharma’s Attruby (acoramidis), an oral transthyretin (TTR) stabiliser, to treat adults with transthyretin amyloid cardiomyopathy (ATTR-CM).

21h

FDA Approves BridgeBio Pharma's Drug For Rare Heart Disease, Poised To Challenge Pfizer In Lucrative Yet Competitive Market

Attruby (acoramidis), an orally-administered near-complete (≥90%) stabilizer of Transthyretin (TTR) for adults with ATTR-CM ...

21h

BridgeBio Pharma, Rigetti Computing, Bath & Body Works And Other Big Stocks Moving Higher On Monday

On Friday, the FDA approved BridgeBio Pharma's Attruby (acoramidis), an orally-administered near-complete (≥90%) stabilizer ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results